THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...
AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid arthritis, with data for ulcerative colitis anticipated in Q4 2025. AnaptysBio, Inc. announced positive results from a Phase ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback